Exelixis (EXEL) Non-Current Debt (2010 - 2016)
Exelixis (EXEL) recorded quarterly Non-Current Debt of $80.0 million in Q1 2016, little changed quarter-over-quarter from $80.0 million in Q4 2015, and little changed on a YoY basis from $80.0 million in Q2 2015.
Exelixis (EXEL) Non-Current Debt (2010 - 2016) Analysis & Trends
Exelixis' Non-Current Debt history runs 7 years deep, the most recent figure standing at $80.0 million for Q1 2016.
- In Q1 2016, Non-Current Debt changed 0.0% year-over-year to $80.0 million; the TTM figure through Mar 2016 stood at $80.0 million (changed 0.0% YoY), while the FY2015 annual figure was $80.0 million, changed 0.0% from the prior year.
- Non-Current Debt was $80.0 million for Q1 2016 at Exelixis, roughly flat from $80.0 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $84.5 million in Q1 2012 to a low of $80.0 million in Q3 2014.
- Historically, Non-Current Debt has averaged $81.0 million across 5 years, with a median of $80.2 million in 2014.
- The sharpest annual moves came in 2012 and 2015: Non-Current Debt fell 3.72% in 2012, then changed 0.0% in 2015.
- A 5-year view of Non-Current Debt shows it stood at $82.1 million in 2012, then slipped by 2.15% to $80.3 million in 2013, then dropped by 0.41% to $80.0 million in 2014, then changed by 0.0% to $80.0 million in 2015, then changed by 0.0% to $80.0 million in 2016.
- The last three Non-Current Debt figures came in at $80.0 million (Q1 2016), $80.0 million (Q4 2015), and $80.0 million (Q3 2015), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Exelixis | 13.37 Bn | 12.59 Bn | 590.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2016 | 80.00 Mn |
| Mar 31, 2016 | 80.00 Mn |
| Dec 31, 2015 | 80.00 Mn |
| Dec 31, 2015 | 80.00 Mn |
| Sep 30, 2015 | 80.00 Mn |
| Sep 30, 2015 | 80.00 Mn |
| Jun 30, 2015 | 80.00 Mn |
| Jun 30, 2015 | 80.00 Mn |
| Mar 31, 2015 | 80.00 Mn |
| Mar 31, 2015 | 80.00 Mn |
| Dec 31, 2014 | 80.00 Mn |
| Dec 31, 2014 | 80.00 Mn |
| Sep 30, 2014 | 80.00 Mn |
| Sep 30, 2014 | 80.00 Mn |
| Jun 30, 2014 | 80.06 Mn |
| Jun 30, 2014 | 80.06 Mn |
| Mar 31, 2014 | 80.22 Mn |
| Mar 31, 2014 | 80.22 Mn |
| Dec 31, 2013 | 80.33 Mn |
| Dec 31, 2013 | 80.33 Mn |